Clinical and experimental rheumatology最新文献

{"title":"Cytokine-involved phenotyping identifies a high-risk inflammatory cluster in treatment-naïve Takayasu's arteritis.","authors":"Yaxin Zhang, Shiyu Yang, Hua Liao, Taotao Li, Lili Pan","doi":"10.55563/clinexprheumatol/xsbqa9","DOIUrl":"https://doi.org/10.55563/clinexprheumatol/xsbqa9","url":null,"abstract":"<p><strong>Objectives: </strong>Takayasu's arteritis (TAK) is a clinically heterogeneous large-vessel vasculitis. Conventional inflammatory markers such as erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) may not adequately reflect underlying immune activation or predict long-term outcomes. We aimed to identify immune phenotypes based on serum cytokine profiles and evaluate their clinical relevance in treatment-naïve TAK.</p><p><strong>Methods: </strong>We performed an unsupervised two-step cluster analysis in a cohort of 95 treatment-naïve patients with TAK. Serum levels of 12 cytokines were measured at baseline and clustering incorporated cytokine profiles together with selected clinical variables, including age at onset, disease duration, ESR and CRP. Clinical outcomes were evaluated using multivariable Cox regression models adjusting for disease duration and treatment exposure. A cytokine-involved scoring system was developed for phenotype classification and internally evaluated.</p><p><strong>Results: </strong>Three distinct immune phenotypes were identified. Cluster 2 exhibited multiplex cytokine activation, characterised by elevated interleukin (IL)-1β, IL-2, IL-4, IL-10, tumour necrosis factor-α (TNF-α) and interferon (IFN)-α with the worst outcomes: high relapse (50.0%), refractory disease (41.7%), and mortality (16.7%). Cluster 1 showed an acute phase response (high ESR, CRP, IL-6, IFN-γ), more active disease, and increased relapse risk (41.7%). Cluster 3 had a noninflammatory phenotype, the highest remission (74.5%), and lowest relapse (4.3%). A cytokine-involved scoring model accurately classified phenotype (accuracy 85.2%, AUC 0.964).</p><p><strong>Conclusions: </strong>Cytokine-involved phenotyping may provide a preliminary framework for risk stratification in treatment-naïve TAK. The multiplex cytokine activation phenotype appears to be associated with adverse clinical outcomes, although further validation in larger cohorts is required.</p>","PeriodicalId":10274,"journal":{"name":"Clinical and experimental rheumatology","volume":" ","pages":""},"PeriodicalIF":3.2,"publicationDate":"2026-10-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149206546","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Damage accrual predicts the development of lymphoma in primary Sjögren's disease.","authors":"Ana M Abrantes, Pedro Gaspar, David A Isenberg","doi":"10.55563/clinexprheumatol/yi12xl","DOIUrl":"https://doi.org/10.55563/clinexprheumatol/yi12xl","url":null,"abstract":"<p><strong>Objectives: </strong>To study whether damage and its kinetics are associated with mortality and lymphoma development in primary Sjögren's disease (pSjD).</p><p><strong>Methods: </strong>Single-centre retrospective cohort study including patients with pSjD. Damage was assessed yearly using the Sjögren Syndrome (SS) damage index (DI) (SSDI) and SS Disease DI (SSDDI) scores. Early damage: damage occurring in the first year after diagnosis; early damage increase: increase of ≥1 point in the first 5 years. SSDDI and SSDI scores' domains were compared with two-sample test of proportions. Cox regression was performed to investigate predictors of mortality and lymphoma. A p<0.05 was considered statistically significant.</p><p><strong>Results: </strong>We included 208 patients with pSjD (female: 93.8%; mean age at diagnosis/onset: 49.9±14.9/45.6±15.0 years; mean follow-up time: 14.1±9.2 years). Damage affected 79.3% and 85.1% patients, using SSDDI and SSDI scores, respectively. Age at diagnosis (per one-unit increase HR 1.1, 95%CI 1.1-1.2) and at onset (per one-unit increase HR 1.1, 95%CI 1.0-1.2) predicted mortality. Damage and early damage increase did not predict mortality with either score. Seventeen patients (8.2%) developed lymphoma. Early damage increases predicted lymphoma in both scores (SSDDI: HR 14.5, 95% CI 1.8-115; SSDI: HR 12.8, 95% CI 1.5-108.1). Early damage variation, damage variation, and cumulative damage were also predictors of lymphoma.</p><p><strong>Conclusions: </strong>Although damage was not associated with mortality, age at diagnosis and onset of symptoms were risk factors for mortality in pSjD. Cumulative and evolving damage, especially in the first years of disease, should raise concern about the possible development of lymphoma in these patients.</p>","PeriodicalId":10274,"journal":{"name":"Clinical and experimental rheumatology","volume":" ","pages":""},"PeriodicalIF":3.2,"publicationDate":"2026-10-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149206614","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association between serum transaminase elevations and clinical course in patients with familial Mediterranean fever.","authors":"Nihan Şentürk Öztaş, Rabia Deniz, Emin Oguz, Cigdem Cetin, Ezgi Sahin, Ceren Oyku Aydogan, Bahar Artim Esen, Murat Inanc, Lale Ocal, Ahmet Gül","doi":"10.55563/clinexprheumatol/4in59l","DOIUrl":"https://doi.org/10.55563/clinexprheumatol/4in59l","url":null,"abstract":"<p><strong>Objectives: </strong>To evaluate the clinical features, disease course, genetics, and treatment responses of familial Mediterranean fever (FMF) patients with elevated serum transaminase levels.</p><p><strong>Methods: </strong>The charts of the FMF patients with at least one year of follow-up were retrospectively investigated for the presence of elevated serum transaminase levels. The genetic and clinical findings and disease course of identified patients were compared with a group of FMF patients with no transaminase elevations.</p><p><strong>Results: </strong>A retrospective chart review included 780 registered patients diagnosed with FMF. Forty-two patients (5.3%) were excluded because of the insufficient follow-up duration, associated viral hepatitis, alcoholic hepatitis, and biopsy-proven liver amyloidosis. A total of 83 patients (11.2%) with elevated serum transaminase levels were identified, and their findings were compared with a control group of 655 patients with no transaminase elevation. FMF attacks began at a significantly older age (17.0±12.9 vs. 12.4±9.0 years, p=0.01), and the percentage of patients experiencing more frequent (≥ 3 attacks/month) attacks was higher (35.4% vs. 24.1%, p=0.01) in the elevated transaminase group. No significant differences were observed between the two groups regarding age at diagnosis, delay in diagnosis, presenting features of FMF, CRP levels at baseline and during attacks, frequency of amyloidosis, and the colchicine dose, as well as the frequency of patients requiring anti-IL-1 treatments. The frequency of MEFV gene exon 10 mutations and p.M694V homozygosity did not differ significantly between the groups. Hepatosteatosis was observed by abdominal ultrasonography in 46.7% of the patients with elevated liver enzymes. A follow-up study after 6 years revealed that transaminase levels remained elevated in 21 out of 49 patients (42.9%), and one patient developed liver cirrhosis.</p><p><strong>Conclusions: </strong>Elevated serum transaminase levels can be detected in approximately 11.2% of FMF patients, and this finding is not associated with colchicine use or manifestations of FMF. Ultrasonographic evidence of hepatosteatosis was observed in nearly half of the patients. Follow-up analysis showed that serum transaminase elevations may persist in 43% of the patients, which suggests further studies to determine whether this abnormality is a feature of FMF or not.</p>","PeriodicalId":10274,"journal":{"name":"Clinical and experimental rheumatology","volume":" ","pages":""},"PeriodicalIF":3.2,"publicationDate":"2026-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149206563","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Therapeutic divergence between polymyalgia rheumatica and giant cell arteritis: lessons from IL-17A inhibition.","authors":"Enmanuel A Leiva-Murillo, Sergio Prieto-González","doi":"10.55563/clinexprheumatol/15avnk","DOIUrl":"https://doi.org/10.55563/clinexprheumatol/15avnk","url":null,"abstract":"","PeriodicalId":10274,"journal":{"name":"Clinical and experimental rheumatology","volume":" ","pages":""},"PeriodicalIF":3.2,"publicationDate":"2026-10-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149179033","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Lung ultrasound as part of a diagnostic algorithm to detect interstitial lung disease in rheumatoid arthritis patients at risk.","authors":"Konstantina Kouna, Ioannis Tomos, Spyridon Katechis, Maria Kallieri, Spyridon Prountzos, Konstantinos Drougkas, Thomas Raptakis, Nikolaos Oikonomopoulos, Dimitrios T Boumpas, Effrosyni D Manali, Theofanis Karageorgas, Antonis Fanouriakis","doi":"10.55563/clinexprheumatol/xgirav","DOIUrl":"https://doi.org/10.55563/clinexprheumatol/xgirav","url":null,"abstract":"<p><strong>Objectives: </strong>Rheumatoid arthritis-associated interstitial lung disease (RA-ILD) affects 5-10% of patients with RA. While lung ultrasound (LUS) shows promise for RA-ILD detection, its role remains inconclusive. We aimed to assess its performance as a screening tool in at-risk RA patients.</p><p><strong>Methods: </strong>We made a cross-sectional study of RA patients, including i) individuals >50 years old with ≥1 risk factor for ILD, and ii) patients with new-onset respiratory symptoms. All patients underwent clinical examination, pulmonary function testing (PFT), LUS, and chest high-resolution computed tomography (HRCT). LUS was considered abnormal in case of ≥5 total B-lines, and diagnostic accuracy was compared against HRCT, using a recent American Thoracic Society definition.</p><p><strong>Results: </strong>We included 103 RA patients (73% women; mean age 63.4 years, median disease duration 7 years, 62% current or ever smokers, 68% seropositive for RF and/or ACPA). The majority (67 patients, 64.4%) reported no respiratory symptoms and had normal lung auscultation. According to ATS definition, 23 patients (22.3%) had ILD. Use of LUS for RA-ILD showed a sensitivity of 60.9% (95% CI: 40.8-77.8%), specificity of 63.7% (95% CI: 52.8-73.4%), and a negative predictive value (NPV) of 85% (95% CI: 73.9-91.9%). In regression and random forest analyses, LUS did not outperform DLCO for the prediction of RA-ILD. However, combination of negative LUS examination with normal DLCO essentially excluded RA-ILD (NPV 100%, 95%CI: 82-100%).</p><p><strong>Conclusions: </strong>Negative LUS in combination with normal DLCO reliably exclude ILD in at-risk RA patients, supporting its role in early RA-ILD detection.</p>","PeriodicalId":10274,"journal":{"name":"Clinical and experimental rheumatology","volume":" ","pages":""},"PeriodicalIF":3.2,"publicationDate":"2026-10-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149179642","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Neutrophil extracellular traps activate lymphocytes in systemic lupus erythematosus.","authors":"Yao Jiang, Yan Lei, Jing Zhu, Yan Xing","doi":"10.55563/clinexprheumatol/jokcfs","DOIUrl":"https://doi.org/10.55563/clinexprheumatol/jokcfs","url":null,"abstract":"<p><strong>Objectives: </strong>The aberrant activation of lymphocytes caused by autoantigens plays a critical role in the pathogenesis of systemic lupus erythematosus (SLE). A large number of autoantigens are released during the formation of neutrophil extracellular traps (NETs), but their pathogenic mechanism in SLE has not been fully elucidated. We therefore investigated the role of NETs by activating lymphocytes in SLE.</p><p><strong>Methods: </strong>Peripheral venous blood samples from 58 patients with SLE and 54 healthy controls were included in this study, and the activated indicators of lymphocytes (HLA-DR and CD69) were analysed by flow cytometry. The NETs levels were quantified and their correlation with the levels of activated lymphocytes were analysed. Polymorphonuclear neutrophils (PMNs) and peripheral blood mononuclear cells (PBMCs) were isolated via gradient density separation. The PMNs were stimulated using phorbol 12-myristate 13-acetate (PMA) to form NETs following incubation with autologous PBMCs. The activation of the lymphocytes was tested via flow cytometry.</p><p><strong>Results: </strong>The elevated expression of HLA-DR and CD69 on CD4+ T and CD19+ B cells was observed in the patients with SLE and positively correlated with the NETs level (p<0.05). In contrast to the control group, the NETs group directly activated the CD4+ T and CD19+ B lymphocytes in vitro by increasing the expression of HLA-DR and CD69 (p<0.05).</p><p><strong>Conclusions: </strong>NETs induced the abnormal activation of T and B lymphocytes, which participated in the pathogenesis of SLE. This finding revealed the synergistic roles of innate immunity mediated by neutrophils and adaptive immunity mediated by lymphocytes.</p>","PeriodicalId":10274,"journal":{"name":"Clinical and experimental rheumatology","volume":" ","pages":""},"PeriodicalIF":3.2,"publicationDate":"2026-10-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149179702","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and safety of glucocorticoids combined with mycophenolate mofetil versus methotrexate in IgG4-related disease: a propensity score-matched retrospective cohort study.","authors":"Liang Liang, Xi Xu, Miao Shao, Hua Ye","doi":"10.55563/clinexprheumatol/lqi0v7","DOIUrl":"https://doi.org/10.55563/clinexprheumatol/lqi0v7","url":null,"abstract":"<p><strong>Objectives: </strong>To compare the efficacy and safety of glucocorticoids (GCs) plus mycophenolate mofetil (MMF) versus methotrexate (MTX) in treatment-naive patients with IgG4-related disease (IgG4-RD).</p><p><strong>Methods: </strong>This retrospective cohort study included 154 treatment-naive patients with IgG4-RD. After 1:1 propensity score matching (PSM), 80 matched patients (40 per group) were analysed. Outcomes at 3, 6, and 12 months included complete response (CR), partial response (PR), overall response rate (ORR), clinical remission, treatment failure, relapse, and adverse events. False Discovery Rate (FDR) correction was applied for multiple comparisons in subgroup and repeated-measures analyses.</p><p><strong>Results: </strong>Baseline characteristics were well balanced after matching. At 6 months, the MMF group showed higher ORR (92.5% vs. 72.5%, p=0.019) and PR (85.0% vs. 62.5%, p=0.022), although these differences did not retain significance after FDR correction (q=0.066 for both). At 12 months, MMF was superior in ORR (87.5% vs. 62.5%, p=0.010), CR (32.5% vs. 10.0%, p=0.014) and clinical remission rates (85.0% vs. 52.5%, p=0.002). Treatment failure was lower in the MMF group (2.5% vs. 25.0%, p=0.003). In the visceral subgroup, MMF yielded higher clinical remission (90.5% vs. 52.2%, p=0.005). Adverse events were more frequent in the MTX group (22.5% vs. 5.0%; unadjusted p=0.048; after FDR correction, q=0.336). Relapse rates were similar between groups.</p><p><strong>Conclusions: </strong>GCs plus MMF demonstrated better mid- to long-term efficacy and lower treatment failure than GCs plus MTX in this cohort, with potential benefits in patients with visceral involvement. These findings support MMF as a potential option for long-term maintenance therapy and warrant further prospective evaluation.</p>","PeriodicalId":10274,"journal":{"name":"Clinical and experimental rheumatology","volume":" ","pages":""},"PeriodicalIF":3.2,"publicationDate":"2026-10-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149179633","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effectiveness, survival and prescription patterns of Janus kinase inhibitors in rheumatoid arthritis: results of a 5.9-year follow-up from the Italian Study Group of Early Arthritis (GISEA) registry.","authors":"Gilberto Cincinelli, Ennio Giulio Favalli, Marco Fornaro, Elisa Gremese, Chiara Bazzani, Anna Scalvini, Serena Bugatti, Francesca Romana Spinelli, Marco Sebastiani, Alberto Cauli, Francesco Paolo Cantatore, Roberta Foti, Giovanni Lapadula, Gianfranco Ferraccioli, Fabrizio Conti, Florenzo Iannone, Roberto Caporali","doi":"10.55563/clinexprheumatol/oq087g","DOIUrl":"https://doi.org/10.55563/clinexprheumatol/oq087g","url":null,"abstract":"<p><strong>Objectives: </strong>Janus kinase inhibitors (JAKis) have emerged as a valuable treatment option for rheumatoid arthritis (RA). Still, real-world data on their retention and prescription patterns are crucial, especially considering guideline updates. This study aimed to evaluate these aspects in a large Italian RA cohort.</p><p><strong>Methods: </strong>Patients with a diagnosis of RA enrolled in the Italian Study Group on Early Arthritis (GISEA) registry initiating JAKi therapy were included. Demographic and clinical characteristics, disease activity scores and treatment survival were assessed at baseline, at 6, 12, and 24 months and at last available visit or at drug discontinuation. Log-Rank tests and Cox regression analysis were employed to assess drugs survival and factors associated with discontinuation. Prescription patterns and patients selection were analysed across three periods reflecting key events in JAKi utilisation.</p><p><strong>Results: </strong>1303 patients were included. JAKi retention rates at 6, 12, and 24 months were 80.9%, 74.9%, and 61.1%, respectively. Glucocorticoid use, higher disease activity, and significant pain at baseline were associated with shorter retention. Conversely, first-line JAKi therapy after csDMARD failure was associated with longer retention. Prescription patterns shifted over time, with a trend towards earlier JAKi use among younger patients with established disease, and a more cautious approach following safety warnings, including reduced first-line use and less combination therapy.</p><p><strong>Conclusions: </strong>This large real-world study confirms the effectiveness of JAKis in RA, with valuable insights into factors influencing treatment survival and evolving prescription trends.</p>","PeriodicalId":10274,"journal":{"name":"Clinical and experimental rheumatology","volume":" ","pages":""},"PeriodicalIF":3.2,"publicationDate":"2026-10-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149179656","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Machine learning models identify a distinct urinary metabolomic signature in children with non-systemic juvenile idiopathic arthritis.","authors":"Saverio La Bella, Annamaria Porreca, Maria Concetta Cufaro, Virginia Girlando, Marianna Lauriola, Giorgia Spalluto, Beatrice Dufrusine, Armando Di Ludovico, Francesco Chiarelli, Piero Del Boccio, Damiana Pieragostino, Marina Attanasi, Luciana Breda","doi":"10.55563/clinexprheumatol/fyzkgl","DOIUrl":"https://doi.org/10.55563/clinexprheumatol/fyzkgl","url":null,"abstract":"<p><strong>Objectives: </strong>Despite advances in understanding the molecular mechanisms behind juvenile idiopathic arthritis (JIA), reliable non-invasive biomarkers for diagnosis and monitoring remain limited. Urinary metabolomics offers a promising approach to investigate disease-specific metabolic alterations, especially in the paediatric setting. This exploratory study aimed to characterise the urinary metabolomic profile of children with non-systemic JIA with a machine learning-based approach.</p><p><strong>Methods: </strong>We conducted a cross-sectional study including 98 participants under 18 years of age (58 non-systemic JIA patients and 40 healthy controls). Urine samples were collected and analysed by targeted metabolomics. Feature selection was conducted using Boruta and recursive feature elimination (RFE). Supervised machine learning (ML) models, including logistic regression (LR), k-nearest neighbors (KNN), and random forest (RF), were developed and evaluated using stratified 10-fold cross-validation.</p><p><strong>Results: </strong>Univariate analysis did not reveal any statistically significant metabolites between groups after false discovery rate correction. However, a trend towards upregulation was observed in JIA patients for urinary glycine and long-chain acylcarnitines. Boruta and RFE identified a shared subset of informative features, which were used for classification modelling. The RF model achieved the best performance (AUC 0.989; 95% CI: 0.78-1.00), followed by LR (AUC 0.898; 95% CI: 0.78-1.00) and KNN (AUC 0.795; 95% CI: 0.71-0.99).</p><p><strong>Conclusions: </strong>A multivariate approach and supervised ML models revealed a subtle but biologically relevant urinary metabolomic signature in children with non-systemic JIA, leading to highly accurate patient classification. Given the exploratory nature of this research, further studies with larger and more stratified cohorts are needed to confirm these findings.</p>","PeriodicalId":10274,"journal":{"name":"Clinical and experimental rheumatology","volume":" ","pages":""},"PeriodicalIF":3.2,"publicationDate":"2026-10-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149179636","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"After avacopan: endpoint integrity and glucocorticoid-sparing care in antineutrophil cytoplasmic antibody-associated vasculitis.","authors":"Enmanuel A Leiva-Murillo","doi":"10.55563/clinexprheumatol/r3uuom","DOIUrl":"https://doi.org/10.55563/clinexprheumatol/r3uuom","url":null,"abstract":"","PeriodicalId":10274,"journal":{"name":"Clinical and experimental rheumatology","volume":" ","pages":""},"PeriodicalIF":3.2,"publicationDate":"2026-10-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149179686","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}